• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

    10/31/22 9:00:00 AM ET
    $GRCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRCL alert in real time by email

    SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

    (PRNewsfoto/Gracell)

    Conference call and webcast details:

    Monday, November 14, 2022 @ 8:00am ET

    Investor domestic dial-in: (800) 715-9871 

    Investor international dial-in: +1 (646) 307-1963

    Conference ID: 4840587

    Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

    A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

    About Gracell

    Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

    Media contacts

    Marvin Tang


    [email protected]

    Kyle Evans

    [email protected]

    Investor contacts

    Gracie Tong


    [email protected]

    Stephanie Carrington

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-third-quarter-2022-financials-on-monday-november-14-2022-301663084.html

    SOURCE Gracell Biotechnologies Inc.

    Get the next $GRCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRCL

    DatePrice TargetRatingAnalyst
    11/27/2023Outperform
    Evercore ISI
    10/19/2023$11.00Buy
    Stifel
    3/27/2023$7.00Overweight
    Wells Fargo
    12/8/2022$6.00Buy
    H.C. Wainwright
    9/22/2022$12.00Buy
    Citigroup
    8/18/2022Overweight
    Wells Fargo
    6/1/2022$20.00Overweight
    Cantor Fitzgerald
    4/4/2022$18.00Buy
    BTIG Research
    More analyst ratings

    $GRCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gracell Biotechnologies Acquisition Completed

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ("Parent"), and Grey Wolf Merger Su

      2/22/24 8:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by

      2/20/24 7:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM). "We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR ca

      1/29/24 7:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Financials

    Live finance-specific insights

    See more
    • Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023Presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM); updated data to be reported as an oral presentation at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition (ASH 2023)On track to submit IND filings for planned Phase 1 clinical tr

      11/13/23 7:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time. Conference call and webcast details:Monday, Nov

      10/30/23 8:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLEClosed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash run

      8/14/23 7:15:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

      Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO). In this role, Dr. Li will oversee Gracell's clinical development activities, including the advancement of its pipeline of autologous and allogeneic product candidates across the Company's multiple proprie

      8/1/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

      SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including structuring, negotiating and executing of strategic alliances and collaborations.

      7/19/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Gracell Biotechnologies Inc.

      15-12G - Gracell Biotechnologies Inc. (0001826492) (Filer)

      3/4/24 12:22:13 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:31 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 5:01:37 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:20:07 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Gracell Biotechnologies Inc.

      SC 13G - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:00:10 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Gracell Biotechnologies

      Evercore ISI initiated coverage of Gracell Biotechnologies with a rating of Outperform

      11/27/23 9:23:35 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Gracell Biotechnologies with a new price target

      Stifel initiated coverage of Gracell Biotechnologies with a rating of Buy and set a new price target of $11.00

      10/19/23 7:15:42 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Gracell Biotechnologies with a new price target

      Wells Fargo resumed coverage of Gracell Biotechnologies with a rating of Overweight and set a new price target of $7.00

      3/27/23 8:58:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care